Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease

Author(s): Mohan K. Ghanta, P. Elango, Bhaskar L. V. K. S.*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 37 , 2020

Become EABM
Become Reviewer


Parkinson’s disease is a progressive neurodegenerative disorder of dopaminergic striatal neurons in basal ganglia. Treatment of Parkinson’s disease (PD) through dopamine replacement strategies may provide improvement in early stages and this treatment response is related to dopaminergic neuronal mass which decreases in advanced stages. This treatment failure was revealed by many studies and levodopa treatment became ineffective or toxic in chronic stages of PD. Early diagnosis and neuroprotective agents may be a suitable approach for the treatment of PD. The essentials required for early diagnosis are biomarkers. Characterising the striatal neurons, understanding the status of dopaminergic pathways in different PD stages may reveal the effects of the drugs used in the treatment. This review updates on characterisation of striatal neurons, electrophysiology of dopaminergic pathways in PD, biomarkers of PD, approaches for success of neuroprotective agents in clinical trials. The literature was collected from the articles in database of PubMed, MedLine and other available literature resources.

Keywords: Parkinson's disease, striatal neurons characterisation, electrophysiology, biomarkers, neuroprotection, clinical trials.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 26 October, 2020
Page: [4738 - 4746]
Pages: 9
DOI: 10.2174/1381612826666200217114658
Price: $65

Article Metrics

PDF: 21